Abstract
Throughout six years of the clinical use of cinacalcet, numerous articles have been published, describing cinacalcet therapy in situations outside indications stated in the summary of product characteristics (SPC). Not only in the Czech Republic, such use of a drug is possible.
However, it should be supported by either sufficient literature evidence and/or current scientific knowledge. In such cases, the physician or health care facility take full responsibility for potential adverse effects of the drug.
In the case of cinacalcet from the group of calcimimetics, the most common indications outside the approved SPC are secondary hyperparathyroidism in patients with stage 3 or 4 kidney disease, calciphylaxis of soft tissues and other extraosseous calcifications and the use cinacalcet in patients after kidney transplantation.